PMID-21199269 – Pramlintide Glycemic Control and Weight Meta-Analysis
Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2011;13(2):169-180.
Quick Reference
| Property | Value |
|---|---|
| PMID | 21199269 |
| DOI | 10.1111/j.1463-1326.2010.01322.x |
| Year | 2011 |
| Journal | Diabetes, Obesity and Metabolism |
| Study Type | Systematic Review / Meta-analysis |
| Evidence Level | I |
| Sample | 8 RCTs in T2D and obesity |
| Peptide(s) Studied | Pramlintide |
Key Findings
- Pramlintide was associated with a small but significant reduction in HbA1c in patients with T2D (mean difference ~0.3-0.4%)
- Modest but consistent weight reduction observed in both T2D and obese non-diabetic populations
- Weight loss of approximately 1-2 kg more than placebo in T2D populations
- In obese non-diabetic patients, weight loss up to 3.7 kg placebo-subtracted at 16 weeks
- Increased incidence of nausea (dose-dependent, generally transient)
- No significant increase in hypoglycemia rate vs. placebo (when not combined with excess insulin)
- Weight loss was progressive and sustained over treatment duration
Study Design
Systematic review and meta-analysis of 8 randomized clinical trials. Studies were identified from PubMed, EMBASE, and Cochrane databases. Included both placebo-controlled trials in T2D patients (adjunct to insulin) and obesity trials. Outcomes assessed were HbA1c change, body weight change, nausea incidence, and hypoglycemia rates.
Limitations
- Heterogeneity in trial designs, doses, and patient populations
- Most trials were industry-sponsored
- Relatively small number of included trials (8)
- Limited data on obese non-diabetic populations (fewer trials)
- Nausea assessment varied across trials
Clinical Relevance
This meta-analysis established pramlintide's dual benefit profile: modest glycemic improvement plus weight loss, both of which distinguish it from insulin-only therapy. The weight loss mechanism (amylin-mediated satiety) is complementary to GLP-1-mediated effects, which is the pharmacological rationale behind the development of CagriSema (cagrilintide + semaglutide). Understanding pramlintide's evidence base is essential for practitioners using Cagrilintide or CagriSema, as these next-generation amylin analogs build directly on pramlintide's mechanism.
Related
#research #systematic-review #meta-analysis #evidence-level-I #metabolic #pramlintide